Progress of histone deacetylase inhibitors in treatment of non-Hodgkin lymphoma
10.3760/cma.j.cn115356-20200214-00043
- VernacularTitle:组蛋白去乙酰化酶抑制剂治疗非霍奇金淋巴瘤研究进展
- Author:
Xinrui CHEN
1
;
Teng SONG
;
Ting ZHANG
;
Huaqing WANG
Author Information
1. 天津市人民医院肿瘤诊治中心 天津市中西医结合肿瘤研究所 300121
- From:
Journal of Leukemia & Lymphoma
2020;29(9):573-576
- CountryChina
- Language:Chinese
-
Abstract:
At present, there are few treatment protocols with limited efficacy for relapsed and refractory non-Hodgkin lymphoma (NHL). Histone deacetylase inhibitors (HDACi) exert anti-tumor effects by inhibiting the activation of histone deacetylase (HDAC) and regulating gene expression. HDACi alone or combined with other anti-tumor drugs have shown good efficacy in the treatment of relapsed and refractory NHL. This article reviews the progress of HDACi in the treatment of NHL.
